{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-227407","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.573217+00:00","generated_at":"2026-05-31T01:14:39.042932+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA approves KarXT (Cobenfy) for schizophrenia; triggers $25M milestone for Royalty Pharma from PureTech deal","bullets":["FDA approved KarXT (xanomeline-trospium) for adult schizophrenia; BMS to market as Cobenfy.","Royalty Pharma's March 2023 PureTech deal: $100M upfront, up to $400M milestones, 3% royalty on sales up to $2B (then 1%).","Approval triggers $25M milestone payment from Royalty Pharma to PureTech.","Approval validates Royalty Pharma's investment and unlocks potential future royalty revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-227407","json":"https://secwatch.observer/filing/0001193125-24-227407.json","markdown":"https://secwatch.observer/filing/0001193125-24-227407.md","text":"https://secwatch.observer/filing/0001193125-24-227407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/0001193125-24-227407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/d889954d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:14:39.042932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}